---
title: "Circulating immune signatures during pembrolizumab-based neoadjuvant therapy in early triple-negat"
id: "medrxiv-21-circulating-immune-dynamics-during-neoadjuvant-chemoimmunotherapy-in-early"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-21-circulating-immune-dynamics-during-neoadjuvant-chemoimmunotherapy-in-early"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.19.26368490v1?rss=1"
published_at: "2026-11-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Circulating immune signatures during pembrolizumab-based neoadjuvant therapy in early triple-negat
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-21-circulating-immune-dynamics-during-neoadjuvant-chemoimmunotherapy-in-early
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.19.26368490v1?rss=1)
- **Published At:** 2026-11-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The cohort included 64 patients with early **triple-negative breast cancer** treated with pembrolizumab-based neoadjuvant chemoimmunotherapy; investigators analyzed 125 peripheral-blood specimens across baseline, on-treatment and pre-surgery time points. - Baseline single-cell RNA sequencing (scRNA-seq) was performed on PBMCs from 22 patients, producing 135,271 quality-controlled cells for transcriptional analyses. - Patient-level pseudo-bulk scRNA-seq analysis found enrichment of **TNF-alpha/NF-kappaB** signaling in cytotoxic T/NK and B cells among non-pCR patients (global q ≤ 3.94e-7). - MYC targets and mTORC1 signaling were increased in cytotoxic T/NK cells from non-pCR patients (both global q = 7.00e-5). - T-cell profiles in patients who achieved **pathological complete response** showed preserved naive/memory features; a higher proportion of CX3CR1-expressing cells in the CD4 memory/activation-like compartment associated with pCR (q = 0.0157; AUC = 0.949). - B-cell transcriptional signals favored naive-like programs in pCR (IGHM/IGHD higher; program score P = 0.029, q = 0.059) while XBP1 expression was higher in non-pCR. - Flow cytometry across treatment identified B-cell remodeling over time. Pre-surgery, switched-memory B-cell **CD38** balance was higher in pCR versus non-pCR patients (62.6% vs 50.0%; P = 0.0086; q = 0.0667; Cliff's delta = 0.651; AUC = 0.825). - Early rises in unswitched-memory B-cell CD38 balance were numerically larger in non-pCR patients; conversely, pre-surgery switched-memory B-cell CD38 balance favored pCR patients. - Authors propose circulating transcriptional states and **CD38**-defined B-cell dynamics as candidate biomarkers for pathological response, and they call for prospective validation. - The source reports ethics approvals and data deposition in Zenodo (DOI provided); no competing interests were declared.
## Clinical Analysis & Structured Key Points
CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER | medRxiv Skip to main content CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER View ORCID Profile Javier Pascual , Maria Rosario Chica-Parrado , Clotilde Costa , Roberto Pineiro , Maria Elena Quiros-Ortega , Alvaro Gonzalez-Ortiz , Ana Godoy , Maria Emilia Dominguez , Nuria Ribelles , Bella Pajares , Antonia Marquez-Aragones , Begona Jimenez-Rodriguez , Pilar Cantizani , Patricia Palacios-Ozores , Esperanza Lopez-Lopez , Patricia Chaves-Guerrero , Jesus Velasco-Suelto , Maria Victoria Ortega-Jimenez , Maria Isabel Hierro-Martin , Martina Alvarez , Enrique de Alava , Rafael Lopez-Lopez , Emilio Alba , View ORCID Profile Inaki Comino-Mendez doi: https://doi.org/10.64898/2026.11.19.26368490 Javier Pascual 1 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Centro de Investigacion Biomedica en Red; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Javier Pascual Maria Rosario Chica-Parrado 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Clotilde Costa 3 Centro de Investigacion Biomedica en Red de Cancer, 28029, Madrid, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Roberto Pineiro 3 Centro de Investigacion Biomedica en Red de Cancer, 28029, Madrid, Spain; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria Elena Quiros-Ortega 4 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Alvaro Gonzalez-Ortiz 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ana Godoy 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria Emilia Dominguez 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nuria Ribelles 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bella Pajares 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Antonia Marquez-Aragones 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Begona Jimenez-Rodriguez 5 Medical Oncology Department, Hospital Regional Universitario de Malaga, 29010, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Pilar Cantizani 5 Medical Oncology Department, Hospital Regional Universitario de Malaga, 29010, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Patricia Palacios-Ozores 6 Oncology Department, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Esperanza Lopez-Lopez 2 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Patricia Chaves-Guerrero 7 Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jesus Velasco-Suelto 8 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Centro de Investigacion Biomedica en Red de Cancer, 28029, Madrid, Spain; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria Victoria Ortega-Jimenez 9 Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Histopathology Department, Hospital Clinico Universitario Virgen de la Victoria de Malaga, 29010, Malaga, Spain; Universidad de Malaga, 29; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Maria Isabel Hierro-Martin 9 Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Histopathology Department, Hospital Clinico Universitario Virgen de la Victoria de Malaga, 29010, Malaga, Spain; Universidad de Malaga, 29; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Martina Alvarez 1 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Centro de Investigacion Biomedica en Red; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Enrique de Alava 10 Institute of Biomedicine of Sevilla (IBiS), Virgen del Rocio University Hospital/CSIC/University of Sevilla/CIBERONC, 41013 Seville, Spain; Department of Normal and Pathological Cytology and Histology, School of Medicine, University of Seville, 41004 Sevi; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rafael Lopez-Lopez 11 Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Oncology Department, Complexo Hospitalario Universitario de Santiago de Compostela (SERGAS), Santiago de Compostela, Find this author on Google Scholar Find this author on PubMed Search for this author on this site Emilio Alba 1 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Centro de Investigacion Biomedica en Red; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Inaki Comino-Mendez 1 Medical Oncology Department, Hospital Universitario Virgen de la Victoria, 29010, Malaga, Spain; Instituto de Investigacion Biomedica de Malaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Centro de Investigacion Biomedica en Red; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Inaki Comino-Mendez For correspondence: icomino8{at}gmail.com Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Background: Pathological complete response (pCR) after pembrolizumab-based neoadjuvant chemoimmunotherapy predicts improved outcomes in early triple-negative breast cancer (TNBC), but circulating immune determinants of response remain poorly characterized. Methods: The study included 64 patients with early TNBC treated with pembrolizumab-based neoadjuvant chemoimmunotherapy. Flow cytometry analyzed 125 peripheral-blood specimens collected at baseline, during treatment and before surgery. Baseline PBMCs from 22 patients underwent scRNA-seq, generating 135,271 quality-controlled cells. Analyses used nonparametric tests, effect sizes, FDR correction and sensitivity analyses. Results: Baseline scRNA-seq identified response-associated transcriptional differences. Patient-level pseudo-bulk analysis revealed enrichment of TNF-alpha/NF-kappaB signaling in cytotoxic T/NK and B cells from non-pCR patients (global q<=3.94e-7), together with MYC targets and mTORC1 signaling in cytotoxic T/NK cells (both global q=7.00e-5). T-cell analyses suggested preserved naive/memory features in pCR, while a higher proportion of CX3CR1-expressing cells within the CD4 memory/activation-like compartment was associated with pCR (q=0.0157; AUC=0.949). In B cells, pCR was associated with a nominally higher naive-like program score (P=0.029; q=0.059), supported by higher IGHM and IGHD signals, whereas XBP1 was higher in non-pCR. Flow cytometry identified treatment-associated B-cell remodeling. At pre-surgery, switched-memory B-cell CD38 balance was higher in pCR than non-pCR patients (62.6% versus 50.0%; P=0.0086; q=0.0667; Cliff's delta=0.651; AUC=0.825) and remained nominally significant in leave-one-patient-out analyses. Early increases in unswitched-memory B-cell CD38 balance were numerically greater in non-pCR patients, whereas pre-surgery switched-memory B-cell CD38 balance was higher in pCR patients. Conclusions: Baseline inflammatory and metabolic pathway enrichment was associated with non-pCR, whereas pCR-associated T-cell findings included a CD4 memory/activation-associated CX3CR1 signal and trends towards preserved naive/memory features. Together with time- and compartment-dependent B-cell remodeling, these findings nominate circulating transcriptional states and CD38-defined B-cell dynamics for prospective validation as candidate biomarkers of pathological response. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by the Provincial Research Ethics Committee of Malaga and the Santiago-Lugo Research Ethics Committee (CEI-SL; approval number 2024/036) and was conducted in accordance with the Declaration of Helsinki. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The raw data supporting the findings of this study have been deposited in Zenodo under DOI: 10.5281/zenodo.23947326 https://doi.org/10.5281/zenodo.23947326 Funder Information Declared Instituto de Salud Carlos III , PMP22/00054 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted November 20, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER Javier Pascual , Maria Rosario Chica-Parrado , Clotilde Costa , Roberto Pineiro , Maria Elena Quiros-Ortega , Alvaro Gonzalez-Ortiz , Ana Godoy , Maria Emilia Dominguez , Nuria Ribelles , Bella Pajares , Antonia Marquez-Aragones , Begona Jimenez-Rodriguez , Pilar Cantizani , Patricia Palacios-Ozores , Esperanza Lopez-Lopez , Patricia Chaves-Guerrero , Jesus Velasco-Suelto , Maria Victoria Ortega-Jimenez , Maria Isabel Hierro-Martin , Martina Alvarez , Enrique de Alava , Rafael Lopez-Lopez , Emilio Alba , Inaki Comino-Mendez medRxiv 2026.11.19.26368490; doi: https://doi.org/10.64898/2026.11.19.26368490 Share This Article: Copy Citation Tools CIRCULATING IMMUNE DYNAMICS DURING NEOADJUVANT CHEMOIMMUNOTHERAPY IN EARLY TRIPLE-NEGATIVE BREAST CANCER Javier Pascual , Maria Rosario Chica-Parrado , Clotilde Costa , Roberto Pineiro , Maria Elena Quiros-Ortega , Alvaro Gonzalez-Ortiz , Ana Godoy , Maria Emilia Dominguez , Nuria Ribelles , Bella Pajares , Antonia Marquez-Aragones , Begona Jimenez-Rodriguez , Pilar Cantizani , Patricia Palacios-Ozores , Esperanza Lopez-Lopez , Patricia Chaves-Guerrero , Jesus Velasco-Suelto , Maria Victoria Ortega-Jimenez , Maria Isabel Hierro-Martin , Martina Alvarez , Enrique de Alava , Rafael Lopez-Lopez , Emilio Alba , Inaki Comino-Mendez medRxiv 2026.11.19.26368490; doi: https://doi.org/10.64898/2026.11.19.26368490 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (642) Allergy and Immunology (928) Anesthesia (355) Cardiovascular Medicine (5059) Dentistry and Oral Medicine (496) Dermatology (432) Emergency Medicine (681) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1703) Epidemiology (16350) Forensic Medicine (37) Gastroenterology (1248) Genetic and Genomic Medicine (7333) Geriatric Medicine (761) Health Economics (1101) Health Informatics (5349) Health Policy (1480) Health Systems and Quality Improvement (1847) Hematology (604) HIV/AIDS (1389) Infectious Diseases (except HIV/AIDS) (16537) Intensive Care and Critical Care Medicine (1210) Medical Education (702) Medical Ethics (157) Nephrology (757) Neurology (7664) Nursing (380) Nutrition (1144) Obstetrics and Gynecology (1308) Occupational and Environmental Health (1046) Oncology (3768) Ophthalmology (1105) Orthopedics (414) Otolaryngology (474) Pain Medicine (508) Palliative Medicine (144) Pathology (727) Pediatrics (1877) Pharmacology and Therapeutics (759) Primary Care Research (793) Psychiatry and Clinical Psychology (6185) Public and Global Health (10051) Radiology and Imaging (2562) Rehabilitation Medicine and Physical Therapy (1540) Respiratory Medicine (1280) Rheumatology (666) Sexual and Reproductive Health (814) Sports Medicine (601) Surgery (809) Toxicology (109) Transplantation (321) Urology (309)
## Related Clinical Research

- [FDA clears Roche’s giredestrant; semaglutide shows efficacy in children with severe obesity](https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-roche-breast-cancer-pill-obesity-drugs.md)
- [Breast cancer survival prediction using HEAL-Surv multimodal distillation](https://medichelpline.com/clinical-feed/medrxiv-15-hierarchical-graph-learning-with-multimodal-distillation-for-breast-cancer.md)
- [FDA approves Roche’s Wilserdly (giredestrant) for ESR1-mutant HR-positive, HER2-negative breast ca](https://medichelpline.com/clinical-feed/stat-news-0-stat-fda-approves-new-breast-cancer-drug-providing-new-option-for-some-patients.md)
- [EHR Phenotype Choice Alters Outcomes: Three Invasive Breast Cancer Definitions Compared in TriNetX](https://medichelpline.com/clinical-feed/plos-one-6-electronic-health-record-phenotype-choice-and-real-world-outcome-estimates-a.md)
- [High-fat Diets Reprogram Intestinal Stem Cells and May Raise Colon Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-high-fat-diets-leave-memory-in-gut-stem-cells-that-may-fuel-colon-cancer.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.